Multicenter clinical trials to determine the efficacy and safety of consolidation and maintenance therapy with ixazomib, lenalidomide, dexamethasone (IRd) therapy in patients with multiple myeloma after autologous stem cell transplantation.
Latest Information Update: 26 May 2022
At a glance
- Drugs Dexamethasone (Primary) ; Ixazomib (Primary) ; Lenalidomide (Primary)
- Indications Multiple myeloma
- Focus Therapeutic Use
Most Recent Events
- 25 May 2022 Status changed from recruiting to active, no longer recruiting.
- 05 Jun 2018 New trial record